COMPASS - COpenhagen MenoPAuSe Study

During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.

NCT Number	NCT07254429
Lead Sponsor	Martin Blomberg Jensen
Conditions	Menopausal Osteoporosis, Bone Markers
Enrollment	192 participants
Start Date	2025-10-02
Primary Completion	2027-12 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-02